Brain microbleeds (BMBs) are perivascular hemosiderin deposits that are visible as small hypointense lesions on gradient-echo T2 weighted magnetic resonance imaging (MRI) sequences. 1 BMBs are considered to be a marker of cerebrovascular disease, particularly cerebral small vessel disease. BMBs are associated with global cognitive dysfunction, 2,3 gait disturbances, 4 (recurrent) stroke, 5, 6 and mortality, 7 emphasizing the potential clinical relevance of these microhemorrhages.
Brain microbleeds (BMBs) are perivascular hemosiderin deposits that are visible as small hypointense lesions on gradient-echo T2 weighted magnetic resonance imaging (MRI) sequences. 1 BMBs are considered to be a marker of cerebrovascular disease, particularly cerebral small vessel disease. BMBs are associated with global cognitive dysfunction, 2,3 gait disturbances, 4 (recurrent) stroke, 5, 6 and mortality, 7 emphasizing the potential clinical relevance of these microhemorrhages.
Hypertension is an important and modifiable risk factor for the occurrence of BMBs. 8, 9 In cohorts with patients at risk for BMBs, such as stroke-free hypertensive patients 10 and lacunar stroke patients, 11 an association has been found between high 24-hour ambulatory blood pressure (BP) levels and the presence of BMBs. However, little is known about risk factors for progression of BMBs, and this in particular is the case for the contribution of ambulatory BP levels. Only a few studies reported follow-up data about BMB progression, mostly in specific or small population, or with wide follow-up intervals within the study. [12] [13] [14] [15] Systolic BP (SBP) at baseline was an important predictor of new BMBs in these studies. However, most studies used office BP measurements, and these are considered less accurate than ambulatory measurements in predicting BP-related end-organ damage.
The aim of our study was to explore BMB progression and the association with 24-hour ambulatory BP levels in essential hypertensive patients after a predefined duration of follow-up of 2 years.
METHODS

Participants
Selection of participants and the collection of baseline data have been described in detail elsewhere. 10 All patients (n = 744) referred to our outpatient department for evaluation of their hypertension between July 2004 and September 2006 were screened for participation in a longitudinal cohort study in hypertensive patients. An experienced internist decided, based on the patients' clinical information provided by the referring physician and independent of the study, whether it was possible to temporarily stop the patient's antihypertensive medication. Patients who continued treatment were excluded from participation (n = 264).
Hypertension was defined as an untreated office SBP ≥140 mm Hg and/or diastolic BP (DBP) ≥90 mm Hg. Patients had to fulfill the following inclusion criteria: (i) age between 18 and 90 years; (ii) no signs of secondary hypertension or chronic renal failure (n = 15 excluded); (iii) no documented diabetes (n = 17 excluded); (iv) no ischemic or valvular heart disease and no atrial fibrillation (n = 26 excluded); (v) no history of symptomatic transient ischemic attacks or stroke (n = 30 excluded); and (vi) no diagnosis of obstructive sleep apnea syndrome (n = 3 excluded). In this way, a total of 389 patients were eligible for inclusion. Of these patients, 221 gave consent to inclusion in this study. Three were excluded because of claustrophobia for MRI. Finally 218 patients were included in the baseline study. All participants gave written informed consent, and the local Medical Ethics Committee approved the study.
Of the 218 patients at baseline, 193 (89%) patients completed the 2-year follow-up measurements and were included in this study. During follow-up, patients were treated for their hypertension according to international guidelines.
BP data
At baseline and at 2 years of follow-up (within 2 weeks before or after brain MRI), conventional office BP and ambulatory BP were measured in the nondominant arm. Office BP was measured by sphygmomanometry (Korotkoff phases I and V) with the patient seated and always by the same investigator (L.H. Henskens). After at least 5 minutes of rest, 3 consecutive measurements were taken, and the mean of all 3 was calculated. Ambulatory BP was measured over a 24-hour period using an oscillometric device with an appropriately sized cuff on the nondominant arm. We used calibrated devices (Spacelabs 90207 or 90217, Spacelabs Healthcare, USA) that were validated and approved by the British Hypertension Society. 16 Monitors were programmed to obtain BP recordings every 15 minutes from 7:00 am to 11:00 pm and every 30 minutes thereafter. Readings with a SBP >240 or <70 mm Hg, a DBP >150 or <40 mm Hg, a mean arterial pressure >200 or <40 mm Hg, or a heart rate >200 or <20 beats per minute were automatically rejected. Data were not edited manually. Day (awake) and night (asleep) periods were determined by excluding a 2-hour transition period around the rising and retiring times that the patient reported in a diary. 10 We calculated mean 24-hour, awake, and asleep SBP and DBP. We also calculated pulse pressure (PP). At baseline, 24-hour BP monitoring was performed twice if possible (preferably within a week), and the mean of both measurements was used for analysis. At baseline, antihypertensive drugs were discontinued at least 2 weeks before the measurements. At follow-up, only 1 24-hour measurement was performed with continuation of antihypertensive medication. Reaching the BP goal of 24-hour SBP <130 mm Hg and DBP <80 mm Hg (according to European Society of Hypertension criteria) 17 was used as a measure for the degree of BP control during follow-up.
Brain MRI
Brain MRI (1.5T) was performed at baseline and after 2 years (±2 weeks) of follow-up. The standardized imaging protocol has been described elsewhere and consisted of axial T2-weighted fast spin echo, fluid-attenuated inversion recovery and T2*-weighted gradient echo sequences, producing 24 slices with a thickness of 5 mm and a 0.5 mm interslice gap. 10 BMBs were defined as punctuate, diameter <5 mm, homogeneous foci of low-signal intensity on T2*-weighted gradient echo images. Symmetric hypointensities in the globi pallidi, likely to represent calcification or iron deposition, and sulcal flow voids from cortical vessels were disregarded. All BMBs were counted one by one. Two experienced vascular neurologists performed baseline rating of BMBs. In case of disagreement, they had a consensus meeting. Cohen's kappa was 0.68. 10 The follow-up MRI scans were rated by 1 neurologist, who, in case of doubt, consulted a second vascular neurologist. The follow-up MRI was directly compared with the baseline MRI. Progression of BMBs was defined as the presence of any new BMB.
Statistical analysis
Parametric data are presented as mean ± SD, nonparametric data are presented as median with minimum-maximum ranges, and categorical variables are presented as number with percentage. To detect group differences, we applied the independent samples t test for normally distributed variables, the Pearson χ 2 statistic for categorical variables, and the MannWhitney U test for variables with skewed distributions. We performed logistic regression analyses to evaluate the associations between BP characteristics and progression of BMBs. After unadjusted analyses (model 1), we adjusted for age and sex (model 2) and additionally for the presence of BMBs at baseline (model 3). Finally, we performed some exploratory analyses by adding vascular risk factors (smoking, glucose level, cholesterol level, body mass index) one by one. Odds ratios (ORs) are presented with corresponding 95% confidence intervals (CIs). A two tailed probability value <0.05 was considered statistically significant. Analyses were performed using the statistical software package SPSS version 16.0, IBM, USA.
RESULTS
Characteristics of the study population (n = 193) are summarized in Table 1 . Of the 25 patients who were not included in the follow-up study, 1 patient had suffered a stroke and was not mobile (this patient did have a BMB at baseline), 10 patients could not have a second MRI (because of illness, migration, implantation of a magnetic device, or claustrophobia), and 14 patients refused a follow-up MRI or 24-hour ambulatory BP measurement. No patients had died.
The nonincluded patients were more often current smokers (n = 8 (32%) vs. n = 30 (16%); P = 0.04) and had a higher cholesterol level (6.3 ± 1.0 vs. 5.8 ± 1.2 mmol/l; P = 0.03) than the patients in the follow-up group. Baseline 24-hour SBP (159 ± 16 mm Hg vs. 150 ± 18 mm Hg; p = 0.013) and 24-hour DBP (98 ± 13 mm Hg vs. 93 ± 11 mm Hg; P = 0.03) were significantly higher in the nonincluded patients. The other baseline characteristics did not significantly differ between the included and nonincluded patients.
Progression of BMBs
At baseline, 29 (15%) patients had BMBs with a total of 88 BMBs. After 2 years of follow-up, 12 patients (6%) showed progression of BMBs. Six of these patients had no BMB at baseline. An example is shown in Figure 1 . In 5 patients with BMBs at baseline (3% of all participants, or 17% of those participants with BMBs at baseline), ≥1 BMBs had "disappeared" during follow-up. One of these patients had disappearance of BMBs but also had 5 new BMBs and was thus defined as "progressive. " In total, 33 (17%) patients had BMBs at follow-up with a total of 98 BMBs (range = 1-32). During follow-up, 3 patients suffered a stroke. None of these patients had progression of BMBs.
Patients with progression of BMBs were significantly older and the prevalence as well as total number of BMBs at baseline was greater compared with those without progression of BMBs. Other cardiovascular risk factors and the use Data are presented as number (percentage), mean ± standard deviation, or median (range). Abbreviations: BMB, brain microbleed; ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker. *P < 0.05; **P < 0.01 (progression vs. no progression).
of cholesterol-lowering drugs, antiplatelet and anticoagulant drugs, and antihypertensive drugs (at baseline and followup) did not differ between those with and without progression (Table 1) .
Ambulatory BP and progression of BMB
All baseline untreated ambulatory BP characteristics were significantly higher in patients with progression (Table 2) . Table 3 presents the (treated) 24-hour BP data at follow-up. The treatment goal of 24-hour BP <130/80 mm Hg was attained in 38% of all patients and did not differ significantly between patients with or without BMB progression. Table 4 shows the results of the logistic regression analyses in which we evaluated the relation between various baseline ambulatory BP characteristics and progression of BMBs. Baseline 24-hour SBP, 24-hour DBP, and 24-hour PP all significantly predicted progression of BMBs, also after correction for age and sex. Similar results were seen for awake and asleep SBP, DBP, and PP.
After additional adjustments for baseline presence of BMBs, the associations remained significant for 24-hour, awake, and asleep SBP, awake DBP, and awake and asleep PP. Abbreviations: BP, blood pressure; DBP, diastolic blood pressure; PP, pulse pressure; SBP, systolic blood pressure. *P < 0.05 (progression vs. no progression).
Exploratory adjustments for vascular risk factors (glucose level, cholesterol level, smoking, body mass index) did not materially change these results (results not shown).
Office BP and progression of BMB
Baseline office SBP was significantly higher in patients with progression of BMB ( Table 2) . In logistic regression analysis (Table 4) , office SBP was associated with progression of BMB but DBP was not.
DISCUSSION
After 2 years of follow-up of a hypertensive patient cohort we found progression of BMBs in 6% of the patients. Baseline 24-hour SBP, 24-hour DBP, and 24-hour PP, as well as awake and asleep SBP, DBP, and PP, are important predictors for progression of BMBs independent of age and sex. Except for 24-hour DBP, asleep DBP, and 24-hour PP, all BP characteristics remained important predictors of progression, independently of the presence of BMBs at baseline.
Progression of BMBs in our study is lower than that in other follow-up studies, which showed progression rates of 10% to 23% after follow-up ranging 2-5 years. [12] [13] [14] [15] This could be because of the younger age of our patients compared with the other studies or because of different patient populations. The relatively short duration of follow-up could also contribute to the lower progression rate. Treatment of hypertension may have mitigated the effect of the (untreated) BP over time. Finally, because the nonincluded patients had higher 24-hour SBP and 24-hour DBP than the follow-up patients, this may have mitigated the progression rate in our study as well.
Previously, we showed an association between ambulatory BP components and the presence of BMBs in a crosssectional analysis. 10 In this follow-up study, we confirm that baseline untreated BP and PP are important predictors for BMB progression despite subsequent treatment. Similar results were seen in other follow-up studies. [12] [13] [14] [15] Results of analysis with office measurement were comparable with ambulatory BP analysis in that SBP seems to be more important than DBP. However, awake DBP was a predictor for BMB progression whereas office DBP was not. In general, ambulatory BP measurements are considered more accurate than office measurements.
The pathogenetic mechanism of high BP and PP leading to BMBs is still speculative. It could be that high BP is just an epiphenomenon of an underlying systemic small vessel endothelial pathology that, among others, leads to BMBs in the brain. This could explain why BP treatment does not stop progression, as it does not treat the endotheliopathy. More plausibly, a high 24-hour BP and PP load could lead to structural changes in the small vessels in the brain with breakdown and leakage of the blood-brain barrier [18] [19] [20] and Abbreviations: BP, blood pressure; DBP, diastolic blood pressure; SBP, systolic blood pressure. Abbreviations: BP, blood pressure; CI, confidence interval; DBP, diastolic blood pressure; OR, odds ratio; PP, pulse pressure; SBP, systolic blood pressure. *P < 0.01; **P < 0.05.
the occurrence of BMBs. Although BP control at the end of follow-up was equal in patients with and without progression, a high BP at the start could still be a risk factor for progression. There will be some vessel damage already, and it takes time to reach an adequate BP level. Antihypertensive treatment could have slowed down, although not stopped, the progression. Whether adequate and early BP intervention could really halt BMB progression remains to be solved. The presence of BMBs at baseline may be a sign of an already advanced stage of endotheliopathy. Therefore, the extent of baseline BMBs could be an important predictor for further progression of BMBs, as indeed has been shown in other studies. 12, 13 This was also found in our study as patients with progression more often had BMBs already at baseline. However, although the presence of BMBs at baseline strongly weakened the association between BP and progression of BMBs, the association between most ambulatory BP characteristics and BMB progression remained significant. This could indicate that there is no point-of-no-return and that adequate BP intervention could still be a possibility to halt BMB progression, although, as said, this remains the subject of research.
The strength of our study is that information was obtained in a homogeneous cohort of patients that are at risk for developing BMBs-namely, hypertensive patients. Moreover, we had a high follow-up rate, and although follow-up duration was rather short, the range of follow-up duration within our study was very strict. Finally, we had baseline as well as follow-up BP data and used 24-hour ambulatory BP monitoring in addition to office BP measurements.
On the other hand, our study also has some limitations. The wide age range requires cautious application of conclusions across all age ranges because age may be an effect modifier in the association between BP level and occurrence of brain damage. The period of follow-up was relatively short, and the number of patients with progression of BMBs was small. This weakens the strength of the statistical analyses, and it did not allow us to consider number of BMBs or deep and lobar BMBs separately, for which some evidence suggests that BP plays a different role. 13 Also a difference in treatment effect of the different antihypertensive drugs was therefore probably not seen. We used the European Society of Hypertension criteria as a measure for the degree of BP control during follow-up, although this probably did not completely cover all BP-related aspects. Finally, in some of our patients with BMBs at baseline, BMBs disappeared at follow-up. Although this was comparable with other studies, [12] [13] [14] [15] it is not clear whether BMBs can really disappear over time. Probably it is because of the imaging technique, although this would also mean that not all newly appearing BMBs reflect true progression.
In conclusion, this study demonstrates in a treated hypertensive population progression of BMBs in 6% of the patients after 2 years of follow-up. Untreated ambulatory 24-hour BP characteristics (including awake and asleep characteristics) at baseline are important predictors for progression of BMBs independent of age and sex. Although the presence of BMBs at baseline weakens the association, most ambulatory 24-hour BP characteristics remain important predictors of progression. Although presence of BMBs could be considered as a sign of an already advanced endotheliopathy, further progression could possibly still be prevented by treating BP, which could have important clinical consequences for the morbidity that is correlated with BMBs. High BP could be a modifiable risk factor for progression of BMBs, and this warrants further study. We suggest a longer followup period during which patients are adequately treated early for their hypertension to see if the progression of BMBs can be halted.
